FY2025 EPS Estimates for Sanara MedTech Lifted by Analyst

Sanara MedTech Inc. (NASDAQ:SMTI - Free Report) - Analysts at Cantor Fitzgerald upped their FY2025 EPS estimates for Sanara MedTech in a research note issued on Thursday, May 15th. Cantor Fitzgerald analyst R. Osborn now expects that the company will post earnings of ($1.78) per share for the year, up from their previous estimate of ($2.43). Cantor Fitzgerald has a "Overweight" rating and a $46.00 price target on the stock. The consensus estimate for Sanara MedTech's current full-year earnings is ($1.10) per share.

Separately, HC Wainwright lifted their price target on shares of Sanara MedTech from $51.00 to $53.00 and gave the company a "buy" rating in a report on Thursday, May 15th.

Sanara MedTech Price Performance

NASDAQ:SMTI traded down $0.60 during trading hours on Monday, hitting $30.39. 27,384 shares of the stock traded hands, compared to its average volume of 26,132. The company has a quick ratio of 2.02, a current ratio of 2.23 and a debt-to-equity ratio of 0.76. Sanara MedTech has a 1 year low of $25.86 and a 1 year high of $39.08. The company has a market cap of $270.11 million, a price-to-earnings ratio of -30.70 and a beta of 1.38. The stock has a 50 day moving average price of $30.91 and a 200 day moving average price of $33.36.

Sanara MedTech (NASDAQ:SMTI - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.10). Sanara MedTech had a negative net margin of 10.71% and a negative return on equity of 19.86%. The firm had revenue of $23.43 million for the quarter, compared to analysts' expectations of $23.48 million.

Hedge Funds Weigh In On Sanara MedTech

Several large investors have recently added to or reduced their stakes in the company. Northern Trust Corp lifted its holdings in Sanara MedTech by 0.9% during the fourth quarter. Northern Trust Corp now owns 40,816 shares of the company's stock valued at $1,355,000 after purchasing an additional 358 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Sanara MedTech by 152.9% in the fourth quarter. Renaissance Technologies LLC now owns 35,400 shares of the company's stock worth $1,175,000 after buying an additional 21,400 shares in the last quarter. Marshall Wace LLP purchased a new position in shares of Sanara MedTech in the fourth quarter worth $1,005,000. Fifth Third Bancorp purchased a new position in shares of Sanara MedTech in the fourth quarter worth $898,000. Finally, Citadel Advisors LLC lifted its holdings in shares of Sanara MedTech by 7.3% in the fourth quarter. Citadel Advisors LLC now owns 21,984 shares of the company's stock worth $730,000 after buying an additional 1,491 shares in the last quarter. Hedge funds and other institutional investors own 8.10% of the company's stock.

About Sanara MedTech

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.